ResMed Inc stock faces pressure amid slowing sleep apnea device demand and insurance reimbursement headwinds

ResMed Inc (ISIN: US75102W1036), a leader in sleep apnea treatments, grapples with weakening US demand for CPAP machines as competition from weight-loss drugs intensifies. Shares have pulled back sharply on the NYSE in USD amid broader medtech sector challenges. US investors should watch reimbursement risks and innovation pipeline for rebound potential.

ResMed Inc stock has come under significant pressure in recent trading sessions on the NYSE in USD, reflecting broader concerns over decelerating demand for continuous positive airway pressure (CPAP) machines, the company's core product. The downturn stems from heightened competition from GLP-1 weight-loss drugs like Ozempic and Wegovy, which are reducing obesity-related sleep apnea cases among patients. As of March 25, 2026, the ResMed Inc stock trades at around $180 USD on the NYSE, down more than 15% over the past month amid these headwinds. US investors, who dominate the shareholder base, face key questions on whether this represents a buying opportunity in a high-quality medtech name or signals deeper structural challenges in the sleep health market.

As of: 25.03.2026

By Elena Vasquez, Senior MedTech Analyst: ResMed's dominance in sleep-disordered breathing solutions is tested by paradigm shifts in obesity treatment, demanding agile adaptation from this Australian-headquartered innovator.

Recent Market Trigger: Demand Slowdown Hits CPAP Sales

The primary catalyst for the recent slide in ResMed Inc stock on the NYSE in USD is verified reports of softening demand for CPAP devices in the US, the company's largest market. Multiple financial news outlets, including Reuters and Bloomberg, confirmed in the last 48 hours that US prescribers are seeing fewer new sleep apnea diagnoses as patients achieve weight loss through GLP-1 agonists. This shift has led to sequential declines in ResMed's mask and device shipments, with industry data showing a 8-10% drop in quarterly unit volumes.

ResMed's fiscal Q2 results, released earlier this month, highlighted the issue: revenue growth slowed to 4% year-over-year, missing analyst expectations, primarily due to lower-than-expected SaaS subscriptions and device sales. Management attributed 60% of the shortfall to US market softness, where CPAP adherence remains a persistent challenge compounded by drug alternatives. The stock reaction was immediate, shedding 12% in the following session on the NYSE in USD.

Why now? The convergence of widespread GLP-1 adoption—now prescribed to over 15 million Americans—and peak CPAP replacement cycles has amplified the visibility of this trend. Investors are recalibrating growth multiples, with forward P/E ratios compressing from 30x to around 22x on the NYSE in USD.

US Investor Relevance: Heavy Domestic Exposure Amplifies Risks

For US investors, ResMed Inc stock carries outsized importance due to the company's 55% revenue reliance on North America, per verified annual report data. The NYSE-listed shares in USD serve as a pure play on US sleep health trends, with minimal currency risk for domestic holders. Medicare reimbursement dynamics, which cover 40% of CPAP usage, add a regulatory layer that Wall Street watches closely.

Recent CMS proposals to tighten CPAP compliance criteria—requiring 4 hours nightly use for 70% of nights—could further crimp volumes, as only 50% of patients currently meet thresholds. Analysts from JPMorgan and Goldman Sachs, in notes dated March 23, 2026, cut price targets to $200 USD on the NYSE, citing a potential 5-7% hit to 2026 EBITDA from reimbursement squeezes.

This matters now because ResMed's $40 billion market cap on the NYSE in USD positions it as a bellwether for medtech amid obesity drug disruption. US portfolio managers, holding 70% of shares, must weigh the 2.5% dividend yield against growth deceleration risks.

Competition from GLP-1 Drugs Reshapes Sleep Apnea Landscape

GLP-1 agonists from Novo Nordisk and Eli Lilly are not just trimming waistlines; they are slashing sleep apnea incidence by 40-50% in treated patients, per clinical studies published in JAMA last week. ResMed Inc stock on the NYSE in USD is bearing the brunt, as CPAP remains the gold standard for moderate-to-severe cases, but fewer qualify post-weight loss.

ResMed's AirSense 11 platform, which drove 20% of sales growth in 2025, now faces volume headwinds. Company data shows US auto-titrating device shipments down 9% quarter-over-quarter. Competitors like Philips Respironics, still recovering from 2021 recall issues, are gaining share with cheaper alternatives, pressuring ResMed's 60% US market penetration.

Management's pivot to digital health—myAir app subscriptions up 25%—offers partial mitigation, but analysts question sustainability without new device cycles. Forward guidance implies flat device revenue through 2026, a sharp departure from 12% CAGR over the prior five years.

Financial Health Remains Solid Amid Headwinds

Despite the pullback, ResMed Inc stock on the NYSE in USD benefits from fortress-like balance sheet metrics. Net cash position exceeds $1.2 billion USD, with operating margins holding at 28%, verified across SEC filings and earnings calls. Free cash flow conversion remains above 90%, funding $500 million annual R&D and a progressive dividend policy.

Gross margins dipped to 53% in Q2 from supply chain normalization, but cloud software segment—15% of revenue—grew 18%, providing diversification. Debt-to-EBITDA at 0.8x underscores low leverage, appealing to value-oriented US investors scanning for medtech dips.

Valuation-wise, EV/EBITDA at 18x forward looks reasonable versus peers like Intuitive Surgical at 50x, but growth repricing tempers enthusiasm. Consensus 2026 EPS estimates of $7.80 USD imply 8% growth, down from prior 15% forecasts.

Innovation Pipeline and International Growth as Catalysts

ResMed is countering US softness with pipeline advancements, including next-gen AirCurve bilevel devices launching Q3 2026, promising 20% better adherence via AI-driven therapy adjustments. Out-of-sleep products like the NightOwl oximeter expand into cardiac monitoring, targeting $2 billion TAM.

International markets—EMEA and APAC contributing 40% revenue—show resilience, with 7% growth offsetting US declines. China expansion via JV partnerships could add $300 million annualized run-rate by 2028, per management commentary.

For US investors, this geographic balance reduces single-market risk, while M&A war chest positions ResMed for bolt-on deals in digital therapeutics. Recent acquisition of Brightree for $800 million bolsters SaaS offerings, with integration on track for 15% ROI.

Risks and Open Questions for Prudent Investors

Key risks loom for ResMed Inc stock on the NYSE in USD. Regulatory scrutiny on CPAP reimbursement could accelerate if CMS data confirms low adherence, potentially capping pricing power. GLP-1 durability remains uncertain—weight regain post-discontinuation affects 60% of users, per NEJM studies, possibly creating CPAP rebound demand.

Supply chain vulnerabilities persist, with 70% components sourced from Asia amid tariff talks. Patent cliffs on legacy masks by 2027 invite generic erosion. Analyst downgrades from Morgan Stanley cite 10% downside risk to $165 USD on the NYSE if US volumes fall another 5%.

Insider selling—$50 million over 90 days—adds caution, though offset by $1 billion repurchase authorization. Macro recession fears could delay elective sleep studies, amplifying near-term pressure.

Strategic Outlook: Buy the Dip or Wait?

ResMed Inc stock on the NYSE in USD trades at levels unseen since 2023, offering tactical entry for long-term US investors betting on sleep health's $50 billion addressable market. Upside hinges on digital transformation success and GLP-1 offset via novel therapies like hypoglossal nerve stimulation partnerships.

Consensus target of $210 USD implies 17% upside, with bulls highlighting 25% ROIC potential. Bears focus on 5-year revenue CAGR slipping below 8%. Monitor Q3 earnings on April 25 for compliance updates.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.